Abstract
Background Effective anthracycline-free combinations need to be evaluated in metastatic breast cancer (MBC), due to the increased number of patients treated with anthracycline-based adjuvant chemotherapy. Patients and methods Patients with MBC were randomized to paclitaxel and carboplatin (PCb) every 3 weeks or docetaxel and gemcitabine (GDoc) every 3 weeks or weekly paclitaxel (Pw). Trastuzumab was given to patients with HER-2 over-expressing tumors. The primary endpoint of the study was survival. Quality of life (QoL) and cost were assessed. Results Totally, 416 eligible patients entered the study. Median survival times were 29.9 months for PCb, 26.9 for GDoc and 41.0 for Pw (P = 0.037). According to multivariate analysis, adjuvant chemotherapy, >1 metastatic sites, lack of maintenance hormonal therapy, and worse performance status (PS) were significant adverse prognostic factors for survival, while Pw when compared to GDoc improved survival (P = 0.03), as well as when compared to PCb in the subgroup of patients with PS = 1 (P = 0.01, treatment by PS interaction P = 0.03). No significant differences in terms of time to progression were found. Severe myelotoxicity and mucositis were more frequent with GDoc, while severe neuropathy with PCb and Pw. QoL changes did not differ significantly between treatment groups, while cost analysis favored Pw. Conclusions Pw appears to be the most preferable choice among the 3 anthracycline-free taxanes-based regimens tested in the present study.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
Ellis MJ, Hayes DF, Lippman M (2000) Treatment in metastatic breast cancer. In: Harris JR (ed) Disease of the breast, 2nd edn. Lippincot Williams & Wilkins, Philadelphia, pp 749–797
Fountzilas G, Dimopoulos AM, Papadimitriou C et al (1998) First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 9:1031–1034
Perez EA, Hillman DW, Stella PJ et al (2000) A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 88:124–131
Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10:211–215
Fountzilas G, Nicolaides C, Bafaloukos D et al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18:503–509
Seidman AD, Hudis CA, Albanell J et al (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361
Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A et al (2001) Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12:1545–1551
Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983–5992
Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517–1526
Cavalli F, Beer M, Martz G et al (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) 286:5–8
Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
Kind P (1996) The EuroQol Instrument: an index of health-related quality of life. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott Raven, Philadelphia, 191:201
Greiner W, Weijnen T, Nieuwenhuizen M et al (2003) A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 4:222–231
Fountzilas G, Dimopoulos MA, Dafni U et al (2006) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in advanced breast cancer (ABC). Ann Oncol 17:ix70
Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963–974
Efron B, Tibshirani RJ (1993) An introduction to the Bootstrap. Monographs on statistics and applied probability. Chapman and Hall/CRC, Boca Raton, pp 1–430
Moher D (1998) CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated standards of reporting trials. JAMA 279:1489–1491
Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665–685
Perez EA, Vogel CL, Irwin DH et al (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216–4223
Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649
Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792
Pickard AS, Wilke CT, Lin HW et al (2007) Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25:365–384
Conner-Spady BL, Cumming C, Nabholtz JM et al (2005) A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 36:251–259
Acknowledgements
The authors wish to thank Ms. Irene Grimani (MSc), HeCOG Data Office, Athens for the statistical analysis, Ms. Evita Fragou and Ms. Dimitra Katsala for monitoring the study, Ms. Maria Moschoni, HeCOG Data Office, Athens for coordinating the data management, and Ms. Stella Dallidou for secretarial assistance. Most of all the investigators wish to express their gratitude to the patients and their families who had trusted us and participated in the trial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fountzilas, G., Dafni, U., Dimopoulos, M.A. et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. Breast Cancer Res Treat 115, 87–99 (2009). https://doi.org/10.1007/s10549-008-0047-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0047-9